Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Receivables (2016 - 2026)

Cumberland Pharmaceuticals' Receivables history spans 16 years, with the latest figure at $16.9 million for Q4 2025.

  • On a quarterly basis, Receivables rose 44.81% to $16.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $16.9 million, a 44.81% increase, with the full-year FY2025 number at $16.9 million, up 44.81% from a year prior.
  • Receivables hit $16.9 million in Q4 2025 for Cumberland Pharmaceuticals, up from $10.4 million in the prior quarter.
  • Over the last five years, Receivables for CPIX hit a ceiling of $16.9 million in Q4 2025 and a floor of $6.9 million in Q4 2021.
  • Historically, Receivables has averaged $11.9 million across 5 years, with a median of $11.7 million in 2024.
  • The widest YoY moves for Receivables: up 110.92% in 2021, down 44.44% in 2021.
  • Tracing CPIX's Receivables over 5 years: stood at $6.9 million in 2021, then skyrocketed by 91.41% to $13.2 million in 2022, then decreased by 25.87% to $9.8 million in 2023, then increased by 19.91% to $11.7 million in 2024, then skyrocketed by 44.81% to $16.9 million in 2025.
  • Business Quant data shows Receivables for CPIX at $16.9 million in Q4 2025, $10.4 million in Q3 2025, and $10.3 million in Q2 2025.